Cidara's FDA Approval of Antifungal Treatment Fails to Boost Stock Amid Lower Q4 Earnings.
TL;DR Summary
Cidara Therapeutics received FDA approval for its antifungal treatment, Rezzayo, for treating candidemia and invasive candidiasis in adults with limited or no alternative treatment options. However, the company's Q4 earnings report showed lower than expected revenues and an EPS loss, causing a 15.8% drop in its stock price. The FDA approval enables Cidara to receive a $20 million regulatory milestone payment under its agreement with Melinta Therapeutics.
Topics:business#antifungal-treatment#cidara-therapeutics#earnings-report#fda-approval#healthcare#rezzayo
- Cidara's Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment Yahoo Finance
- FDA signs off on Cidara's antifungal Rezzayo for candidiasis FiercePharma
- Cidara stock dips despite FDA approval of antifungal drug Rezzayo Seeking Alpha
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Yahoo Finance
- Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today? InvestorPlace
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
79%
314 → 67 words
Want the full story? Read the original article
Read on Yahoo Finance